Further efficacy endpoints
BLOOD
Treatment with survodutide or semaglutide reduced the mean 7-point self-monitoring of blood glucose (SMBG) level to a greater extent than placebo at week 16; the maximum mean ± SD decrease from baseline was observed in DG3 (−3.03±2.47 mmol/l; Change from baseline in 7-point SMBG. Blood glucose measurements were collected before each meal (assuming three meals a day), approximately 2 h after each meal and at bedtime on a single day during screening (baseline) and a single day between the last dose of study drug and EoT (week 16). Mean overall time points represent the mean per participant per visit of the seven blood glucose measurements at baseline and week 16. Data are presented per DG. The centre line denotes the median value, with the symbols within the boxes denoting the mean. The box boundaries mark the upper and lower quartile of the dataset. The whiskers indicate the variability of the data; whiskers are drawn to the nearest value within 1.5× the IQR of the upper and lower quartiles. Any observations outside of these values are plotted with symbols. Minor treatment effects were observed for all domains of the TFEQ-R18 V2, hunger VAS and PGI-S; a full description of these results is given in the 